LIGAND PHARMACEUTICALS INCORPORATED Finance Lease, Right-of-Use Asset, after Accumulated Amortization
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $2.07 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-02-27
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.07M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.77M.
- 2024-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.94M.
- 2024-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $3.08M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2025-12-31 | $2.07M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $2.77M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $2.94M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $3.08M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $3.22M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $3.39M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $3.57M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $3.76M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $3.94M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $4.09M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $14.44M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $15.03M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $15.62M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $16.20M 10-K · filed 2023-02-28 | $16.21M 10-K · filed 2022-02-28 |
| 2021-09-30 | $16.80M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $17.38M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $17.95M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $15.84M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $84.00K 10-K · filed 2021-02-24 |